TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc.’s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn’s Disease and Ulcerative Colitis, collectively known as “inflammatory bowel disease” (IBD).
IBD affects almost 200,000 Canadians, and many millions of others worldwide. The incidence of IBD is increasing, particularly in young children. There is no cure for IBD, and treatment options are limited and often inadequate.
Hey, check out all the research scientist jobs. Post your resume today!